BioCentury on BioBusiness,
Next steps for NPS after regaining global rights to Gattex, Natpara
Monday, March 25, 2013
Now that NPS
Pharmaceuticals Inc. has regained worldwide rights to two Orphan drugs
at a discount, the biotech must focus on building its global footprint.
Last week, Takeda
Pharmaceutical Co. Ltd. returned ex-North American rights to NPS for
Gattex/Revestive teduglutide and Natpara/Preotact recombinant human parathyroid
hormone 1-84 (PTH). Takeda, which gained the drugs as part of its 2011
acquisition of Nycomed, will receive 6.1 million NPS shares up front. The
shares are valued at $54.9 million based on NPS's closing price of $9.04 on
March 18, the day before the deal was announced.
words displayed of
To read this article, you must be an Archives subscriber. Please choose one of the options below.
All contents Copyright © 1993-2013 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
If you are a current subscriber, log in below or in the upper right corner of this
Whether you want an individual subscription or need a global group license, we have the products,
the experience and the customer support that biopharma executives, researchers, investors, service providers,
and industry stakeholders have trusted for nearly two decades.
Let our Subscriber Services team customize the best intelligence package available in the industry to meet your needs.
Free Trial 4 Weeks of Access
Get a 4-week free trial subscription to see the important articles you are missing.
Get 4 Weeks Free
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]